Acta Diabetologica最新文献

{"title":"High glucose mediates diabetic peripheral neuropathy by inducing Schwann cells apoptosis through the Dgkh/PKC-α signaling pathway.","authors":"Linhui Zuo, Minli Qu, Mengru Zhang, Peng Cheng, Min Guo, Dinesh Selvarajah, Solomon Tesfaye, Jing Wu","doi":"10.1007/s00592-025-02553-9","DOIUrl":"https://doi.org/10.1007/s00592-025-02553-9","url":null,"abstract":"<p><strong>Objective: </strong>Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes. The increased apoptosis of Schwann cells (SCs) induced by high glucose (HG) is significant in the pathogenesis of DPN, but the mechanism remains unclear. Diacylglycerol kinase eta (Dgkh) is a member of the diacylglycerol kinases (DGKs) family that participates in glucose uptake, utilization, and energy homeostasis. But its role in DPN has not been reported.</p><p><strong>Methods: </strong>Streptozotocin (STZ)-induced SD rats were used as an animal model of DPN and human Schwann cells (HSCs) were used as an in vitro model of simulated HG conditions. Behavioral tests, histopathology, the mRNA and protein expression levels were detected in vivo. Further, Dgkh was knocked down in vitro, and PKC-α agonist PMA and inhibitor Ro 31-8220 were added to HSCs to observe the effect of Dgkh/PKC-α on HSCs apoptosis.</p><p><strong>Results: </strong>The mechanical and thermal pain thresholds were significantly decreased in DPN rats induced by STZ. The increased apoptosis of the sciatic nerve in STZ-induced DPN rats is accompanied by the upregulation of Dgkh expression. HG leads to increased HSCs apoptosis by Dgkh increased expression. Meanwhile, the knockdown of Dgkh significantly improved HSCs apoptosis induced by HG. PMA effectively improved apoptosis in HG-induced HSCs, but did not affect Dgkh expression. And we discovered that the apoptosis of HSCs reversed by Dgkh knockdown vanished when the PKC-α inhibitor Ro 31-8220 was added.</p><p><strong>Conclusion: </strong>Dgkh expression increased under HG conditions and triggered apoptosis of HSCs, boosting DPN via inhibiting PKC-α.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144537710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmasking heterogeneity in type 2 diabetes: the clinical relevance of phenotyping in the era of precision medicine","authors":"Salvatore Corrao,&nbsp;Massimo Federici","doi":"10.1007/s00592-025-02556-6","DOIUrl":"10.1007/s00592-025-02556-6","url":null,"abstract":"<div><p>Despite its widespread use in clinical practice, the traditional dichotomous classification of diabetes into type 1 and type 2 fails to capture the marked heterogeneity observed in real-world patients, particularly those with type 2 diabetes mellitus (T2DM). The increasing recognition of the complex interplay between insulin resistance, beta-cell dysfunction, autoimmunity, and genetic predisposition has led to the development of phenotypic classification systems that aim to individualize care beyond glycemic targets. Ahlqvist et al. made a major contribution to this field by identifying five clinically meaningful clusters of adult-onset diabetes using routine clinical variables. These clusters differ in their metabolic profiles, complication risks, and therapeutic needs, offering a pragmatic starting point for personalized diabetology. Their clinical relevance has been further explored and validated by follow-up studies that include detailed metabolic phenotyping, cardiac imaging, and genetic analyses. Nevertheless, enthusiasm for cluster-based models must be tempered by critical appraisal. Evidence from large trials suggests that continuous clinical features may better predict disease progression and treatment response than static cluster assignments. Furthermore, these models have yet to be integrated into clinical guidelines or electronic decision-support systems. This Perspective argues for a multidimensional and dynamic approach to diabetes phenotyping, combining clinical, biochemical, imaging, and genetic data to reflect the evolving nature of the disease. Such a framework could enable more precise stratification and intervention, moving toward truly personalized diabetes care. Integrating these models into real-world settings represents the next frontier in precision diabetology.</p></div>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"62 8","pages":"1167 - 1172"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144537711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New generation agents for glycemic control and diabetic retinopathy progression: what we need to know?","authors":"Stela Vujosevic, Caterina Toma, Anna Ferrulli, Stefano De Cillà, Paolo Nucci, Livio Luzi","doi":"10.1007/s00592-025-02552-w","DOIUrl":"https://doi.org/10.1007/s00592-025-02552-w","url":null,"abstract":"<p><strong>Aims: </strong>To report on the current evidence of early worsening of diabetic retinopathy (EWDR) in patients treated with new-generation antidiabetic agents, with a focus on glucagon-like peptide-1 receptor agonists (GLP1-RA).</p><p><strong>Methods: </strong>A comprehensive analysis of current literature was conducted, with a focus on studies evaluating the impact of glycemic control strategies and GLP1-RA on DR progression. References from landmark studies and recent trials were analyzed.</p><p><strong>Results: </strong>Intensive glycemic control, while effective in reducing long-term microvascular complications including DR, has been associated with EWDR, particularly in cases with rapid HbA1c reductions. Emerging evidence links novel antidiabetic agents, including GLP1-RA, with increased risk of EWDR, though different studies have conflicting results. However, the risk of EWDR seems not to be directly linked to retinal toxicity from specific antidiabetic agents, but more likely to the rapid glycemic improvement. Risk factors for EWDR in these patients include higher baseline HbA1c, rapid and significant reductions in HbA1c levels during the first months of treatment, longer duration of diabetes, and more advanced stages of DR at baseline, while mild or moderate non-proliferative DR seem not be at higher risk of DR progression.</p><p><strong>Conclusions: </strong>While new antidiabetic therapies offer significant benefits for diabetes management, clinicians must be cautious when implementing intensive glycemic control in patients at risk for EWDR. Individualized treatment plans and close monitoring are essential to mitigate risks and optimize outcomes for patients with DR.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144525942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between MASLD phenotypes and the risk of carotid artery plaque: a cross-sectional study among railway workers.","authors":"Jia Pan, Honglian Zeng, Yongyan Song, Xiaoli Zhang, Zihang Wang, Lei Tang, Bo Xie, Rong Peng, Yuanyuan Zhou, Beizhong Liu","doi":"10.1007/s00592-025-02536-w","DOIUrl":"https://doi.org/10.1007/s00592-025-02536-w","url":null,"abstract":"<p><strong>Aims: </strong>Current evidence on the association between metabolic dysfunction-associated steatotic liver disease (MASLD) phenotypes to carotid artery plaque (CAP) remains limited. This study aims to investigate both the association and the potential mediating effects of MASLD phenotypes on the risk of CAP.</p><p><strong>Methods: </strong>In this cross-sectional study, 8644 participants were categorized into five groups based on hepatic steatosis and cardiometabolic criteria: Non-hepatic steatosis, Dysglycemia-MASLD, Overweight-MASLD, Lean-MASLD, and other hepatic steatosis. Multivariable logistic regression analysis was conducted to evaluate the association between MASLD phenotypes and CAP. Mediation analyses were performed to evaluate the mediating effect of dysglycemia and body mass index (BMI) on the relationship between MASLD and CAP.</p><p><strong>Results: </strong>The Dysglycemia-MASLD group exhibited the highest prevalence of CAP of 26.28%, followed by the Lean-MASLD (18.55%) and Overweight-MASLD (14.39%) groups. After adjusting for covariates, Dysglycemia-MASLD patients had a significantly higher risk of CAP, with an OR of 1.599 (95% CI 1.348, 1.896). Notably, individuals under 45 in the Dysglycemia-MASLD and Lean-MASLD subgroups had more than a two-fold increased risk of CAP compared to the Non-hepatic steatosis group, with ORs of 2.393 (95% CI 1.660, 3.416) and 2.724 (95% CI 1.002, 6.221), respectively. Mediation analysis indicated that dysglycemia and BMI mediated 30.86% and 24.49% of the association of MASLD with CAP.</p><p><strong>Conclusion: </strong>The risk of developing CAP varies across MASLD phenotypes, with Dysglycemia-MASLD and Lean-MASLD patients exhibiting the highest risk. Therefore, personalized health management strategies are essential for different MASLD phenotypes.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of a health education intervention based on the behavior change wheel on fear of hypoglycemia behavior in type 2 diabetes mellitus patients: a randomized controlled pilot trial.","authors":"Yueqi Zhao, Lu Zhang, Juan Pang, Jiahui Qiu, Yuying He, Ziwei Xu, Mengyao Han, Lin Liu, Xiaojuan Wan, Jinping Wang, Yu Zhang","doi":"10.1007/s00592-025-02549-5","DOIUrl":"https://doi.org/10.1007/s00592-025-02549-5","url":null,"abstract":"<p><strong>Aims: </strong>To conduct a pilot randomized trial of an intervention based on the behavior change wheel (BCW) to reduce fear of hypoglycemia (FoH) behavior in person with Type 2 diabetes mellitus. Additionally, the study assessed the program's feasibility, acceptability, and preliminary effects.</p><p><strong>Methods: </strong>This study utilized a single-blind, parallel randomized controlled trial design. The intervention included in-person education during hospitalization, online coaching post-discharge and follow-up. Effectiveness was assessed by comparing changes in primary outcomes (FoH behavior and worry), secondary outcomes (impaired hypoglycemia awareness, medical support, and self-management attitudes).</p><p><strong>Results: </strong>Recruitment (82%) and completion rate (100%) indicated feasibility. Qualitative interviews and satisfaction surveys indicated acceptability. The intervention group significantly reduced FoH (behavior and worry) scores compared to the controls (F = 49.060-98.057, P < 0.001, η = 0.632-0.774). Also, lower impaired hypoglycemia awareness (F = 4.036, P = 0.024, η = 0.082) and improved medical support (F = 58.925, P < 0.001, η = 0.664), self-management attitudes (F = 7.931, P = 0.001, η = 0.143) were observed.</p><p><strong>Conclusion: </strong>The BCW-based intervention is feasible, acceptable, and improves not only FoH behavior and worry, but also impaired awareness of hypoglycemia, medical support, and self-management attitudes.</p><p><strong>Trial registration: </strong>The study was retrospective registered on ClinicalTrials.gov (identifier: NCT06197360), registration date: 05/1/2024.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should we treat mild gestational diabetes? An Australian multicentre retrospective cohort study.","authors":"Victoria L Rudland, Emily Hibbert, Jeff Flack, Tang Wong, Vincent W Wong, Mark McLean, Dharmintra Pasupathy, David Simmons, N Wah Cheung","doi":"10.1007/s00592-025-02548-6","DOIUrl":"10.1007/s00592-025-02548-6","url":null,"abstract":"<p><strong>Aims: </strong>The International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria for gestational diabetes (GDM) were widely implemented in Australia, despite limited evidence of better pregnancy outcomes compared to the Australasian Diabetes in Pregnancy Society 1998 (ADIPS1998) criteria. We aimed to evaluate the effect of treatment on pregnancy outcomes for women with 'mild' GDM, defined as GDM diagnosed by one, but not both, sets of criteria.</p><p><strong>Methods: </strong>This multicentre, retrospective cohort study included 17,512 pregnant women in six neighbouring tertiary hospitals in Sydney, Australia, during 2016-2017, all of whom were screened for GDM using a three-point 75 g oral glucose tolerance test. Three hospitals diagnosed and treated GDM according to ADIPS1998 criteria, and three according to IADPSG criteria. For women with 'mild' GDM, we evaluated the effect of treatment versus no treatment on pregnancy outcomes. The primary outcome was large for gestational age. Secondary outcomes were small for gestational age, induction of labour, caesarean section, gestational hypertension, and preeclampsia.</p><p><strong>Results: </strong>2320 (13.2%) pregnant women had 'mild' GDM. Treatment of women with IADPSG-only GDM (i.e. fasting glucose 5.1-5.4 mmol/L (91-97 mg/dL) and/or 1-hour glucose ≥ 10.0 mmol/L (≥ 180 mg/dL)) was associated with less large for gestational age infants than no treatment (RR 0.66, 95%CI 0.49-0.88, p = 0.004) but more induction of labour (RR 1.55, 95%CI 1.03-2.34, p = 0.032). Treatment of women with ADIPS1998-only GDM (i.e. 2-hour glucose 8.0-8.4 mmol/L (144-151 mg/dL)) did not significantly change pregnancy outcomes compared with no treatment.</p><p><strong>Conclusions: </strong>This study highlights the importance of treating even mild IADPSG-GDM to improve pregnancy outcomes.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal liver fibrosis indices as predictors of adverse perinatal outcomes in patients with gestational diabetes mellitus.","authors":"Murad Gezer, Ümit Taşdemir, Ömer Gökhan Eyisoy, Sevdenur Yiğit, Mucize Eriç Özdemir, Oya Demirci","doi":"10.1007/s00592-025-02547-7","DOIUrl":"10.1007/s00592-025-02547-7","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the FIB-4 and APRI scores in patients with gestational diabetes mellitus (GDM) and investigate their associations with neonatal outcomes. Additionally, the predictive value of these non-invasive fibrosis indices for GDM and adverse perinatal outcomes was assessed.</p><p><strong>Materials and methods: </strong>In this retrospective case-control study, 200 pregnant women diagnosed with GDM and 200 healthy controls were analyzed. Data on maternal demographics, laboratory parameters (ALT, AST, platelet count), FIB-4 and APRI scores, perinatal and neonatal outcomes including fetal growth restriction (FGR), oligohydramnios, polyhydramnios, birth weight, gestational age at birth, neonatal cord blood pH, neonatal hypoglycemia, Apgar 1 min. and 5 min. scores, and neonatal intensive care unit (NICU) admission were collected. Logistic regression analyses were performed to identify independent predictors of adverse perinatal outcomes among GDM patients. ROC analysis was used to determine the diagnostic performance of both indices.</p><p><strong>Results: </strong>FIB-4 and APRI scores were significantly higher in GDM patients compared to controls (p < 0.05). Among GDM patients, those with FGR, NICU admission, or neonatal death had significantly elevated FIB-4 scores. Stratification by FIB-4 risk categories revealed that patients with high FIB-4 scores had increased rates of FGR, fetal hypoglycemia, adverse perinatal outcomes, and NICU admission (p < 0.01). ROC analysis for predicting GDM yielded AUC values of 0.577 for FIB-4 and 0.571 for APRI. For predicting adverse perinatal outcomes, the FIB-4 AUC was 0.590, while APRI showed limited predictive ability (AUC = 0.511).</p><p><strong>Conclusion: </strong>FIB-4 can serve as a valuable non-invasive marker for liver dysfunction in GDM and is significantly associated with adverse perinatal outcomes. Despite limited predictive power, these scores may serve as early indicators of hepatic involvement in GDM.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic score from MODY genes is associated with type 1 diabetes and disease characteristics.","authors":"Eulalia Catamo, Andrea Conti, Roberto Franceschi, Klemen Dovc, Camilla Morosini, Davide Tinti, Luana Aldegheri, Stefania Cappellani, Gianluca Tamaro, Angela Zanfardino, Elena Faleschini, Ivana Rabbone, Riccardo Bonfanti, Tadej Battelino, Dario Iafusco, Gianluca Tornese, Antonietta Robino","doi":"10.1007/s00592-025-02544-w","DOIUrl":"10.1007/s00592-025-02544-w","url":null,"abstract":"<p><strong>Aims: </strong>This study evaluates the contribution of common variants in Maturity-Onset Diabetes of the Young (MODY) genes on type 1 diabetes (T1D), using a polygenic score (PGS) approach.</p><p><strong>Methods: </strong>485 children and youth diagnosed with T1D from at least 1 year and 271 healthy controls (HC) were recruited. Personal information (i.e. age, sex, height, weight) were collected for each participant, and clinical information (i.e. age at diagnosis, disease duration, presence of autoantibodies and ketoacidosis at onset (DKA)) were also obtained for T1D subjects. Participants were genotyped using Illumina Infinium Global Screening Array. PGS based on Single Nucleotide Polymorphisms (SNPs) in 16 MODY genes were developed. The association of this PGS with T1D susceptibility and clinical disease characteristics was assessed by regression analysis.</p><p><strong>Results: </strong>A PGS including 335 SNPs in MODY genes discriminates T1D from HC (AUC = 60.1%, AIC = 787.6). This PGS was significantly higher in T1D compared to HC (p-value = 0.0004, pseudo-R2 = 2.85%). Moreover, regression analysis between PGS and T1D clinical characteristics showed higher PGS values in T1D subjects with zinc transporter 8 autoantibodies (ZnT8A) compared with T1D subjects without ZnT8A (p-value = 0.04). A similar trend was also observed for antibodies directed against glutamic acid decarboxylase (GADA), although the association did not reach statistical significance (p-value = 0.06).</p><p><strong>Conclusions: </strong>Our study suggests that a polygenic approach based on MODY genes may discriminate T1D from HC and may contribute to patient stratification, helping to better understand T1D heterogeneity.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial DNA variations and risk of incident gestational diabetes mellitus: a nested case-control study.","authors":"Yuqing Liu, Xiao Li, Maoning Zhao, Yun Zhao, Yuanzhong Zhou, Hongsong Yu, Kai Zhao, Shigang Zhao, Xuejun Shang","doi":"10.1007/s00592-025-02546-8","DOIUrl":"10.1007/s00592-025-02546-8","url":null,"abstract":"<p><strong>Aims: </strong>Gestational diabetes mellitus (GDM) is associated with mitochondrial dysfunction. Mitochondrial DNA (mtDNA) plays a critical role in mitochondrial function, affecting cellular oxidative phosphorylation and ATP supply. This study aims to explore the association between mtDNA variations and GDM in Han Chinese women.</p><p><strong>Methods: </strong>This nested case-control study was conducted among 701 women who developed GDM and 859 contemporaneous controls based on the Chinese Birth Cohort of Environmental and Genetic Factors between 2018 and 2022. Next-generation sequencing was performed on the samples to detect variations in the whole mitochondrial genome. The sequencing data were analyzed, and the differences in the number of mtDNA variations between the two groups were assessed using a t-test. Haplogroup analysis was conducted through the chi-square test. Logistic regression analysis was performed, adjusting for age, BMI, gravidity, and parity, to identify significantly different mtDNA variations between the two groups.</p><p><strong>Results: </strong>Pregnant women with GDM carried fewer mtDNA variants in the D-loop region (11.35 ± 2.77 vs. 11.80 ± 2.86, p = 0.002). Results indicated that m.73A>G (OR: 0.46, 95% CI: 0.28-0.77, p = 0.003), m.185G>A (OR: 0.41, 95% CI: 0.18-0.92, p = 0.030), m.16051A>G (OR: 0.24, 95% CI: 0.07-0.84, p = 0.026), m.16092T>A (OR: 9.21, 95% CI: 1.11-76.42, p = 0.040) and m.16291C>T (OR: 2.35, 95% CI: 1.29-4.28, p = 0.005) in the D-loop region and m.6228C>T (OR: 9.41, 95% CI: 1.14-77.59, p = 0.037) in MT-CO1 gene were found to be significantly different between GDM cases and the controls.</p><p><strong>Conclusions: </strong>This study revealed an association between mtDNA variations and GDM, highlighting the potential that screening for specific mtDNA variants in early pregnancy may predict the development of GDM.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of peripheral blood METTL3 mRNA expression levels with prediabetes and type 2 diabetes mellitus: the Henan rural cohort study.","authors":"Yujie Jiang, Xiaoying Ren, Yuqian Li, Gaohua Chang, Xintao Pan, Yahui Zhang, Chongjian Wang, Xiaotian Liu","doi":"10.1007/s00592-025-02542-y","DOIUrl":"10.1007/s00592-025-02542-y","url":null,"abstract":"<p><strong>Aim: </strong>We aimed to investigate the association of peripheral blood METTL3 (Methyltransferase Like 3) mRNA expression levels with impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM).</p><p><strong>Materials and methods: </strong>A case-control study including 1501 participants from the Henan Rural Cohort study was performed. Peripheral blood METTL3 mRNA expression levels were quantified by qRT-PCR. Binary logistic regression was used to generate odds ratio (OR) and 95% confidence intervals (CI) for the risk of IFG and T2DM. Restricted cubic spline was used to generate the dose-response relationship between METTL3 mRNA expression levels and IFG and T2DM.</p><p><strong>Results: </strong>METTL3 mRNA expression levels were downregulated in T2DM compared with normal glucose tolerance (NGT) (4.03 ± 1.09 vs. 3.96 ± 0.93). After adjusting covariates, the risk of developing IFG in METTL3 mRNA high expression levels group was 30% higher than that in the low expression levels group (OR = 1.30,95%CI:1.02,1.65). Conversely, METTL3 mRNA expression levels were negatively correlated with T2DM(OR = 0.83,95%CI:0.72,0.96) compared to the NGT group. METTL3 mRNA expression levels showed a non-linear correlation with both IFG and T2DM.</p><p><strong>Conclusion: </strong>METTL3 mRNA expression levels exhibited opposing effects on IFG and T2DM. Elevated METTL3 mRNA levels were positively associated with IFG risk but inversely associated with T2DM risk.</p>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}